8.7 Hepatic ImpairmentIn a study in subjects with different degrees of hepatic impairment, no clinically relevantpharmacokinetics (PK) was observed [see Clinical Pharmacology (12.3)].No dose adjustment of RYBELSUS is recommended for patients with hepatic impairment.10 OVERDOSAGEIn the event of overdose, appropriate supportive treatment should be initiated accordingsigns and symptoms. A prolonged period of observation and treatment for these symptomstaking into account the long half-life of RYBELSUS of approximately 1 week.